Skip to main content
SpringerLink
Log in

Short-term outcome of patients with ST-segment elevation myocardial infarction (STEMI) treated with an everolimus-eluting bioresorbable vascular scaffold

  • Original Paper
  • Published:
Clinical Research in Cardiology Aims and scope Submit manuscript

Abstract

Objectives

To evaluate safety and efficacy of the everolimus-eluting bioresorbable scaffold (BVS) in patients with ST-segment elevation myocardial infarction (STEMI).

Background

According to the current guidelines, drug-eluting stents are the treatment of choice in patients with STEMI. BVS represents a new technology capable to restore the native vessel vasomotion and potentially avoiding long-term limitations such as stent thrombosis.

Methods

From October 2012 to May 2013, patients with evidence of STEMI eligible for BVS implantation were included in this study. Exclusion criteria were not defined.

Results

A total of 25 patients, respectively 31 lesions, were treated. Procedural success was achieved in 97 %. Two major adverse cardiac events occurred during hospitalization and follow-up: one patient with cardiogenic shock at the index procedure subsequently died. One patient suffered from instable angina with need for interventional revascularization of a previously untreated vessel. One target vessel failure as a consequence of an intra-procedural dissection was seen. However, no target lesion failure was noted. During 132.7 ± 68.7 days of follow-up none of the patients died.

Conclusion

Our findings suggest that implantation of BVS in STEMI patients is feasible in this small cohort of highly selected patients. Further evaluation in randomized-controlled trials is needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Widimsky P, Wijns W, Fajadet J, de Belder M, Knot J, Aaberge L, Andrikopoulos G, Baz JA, Betriu A, Claeys M, Danchin N, Djambazov S, Erne P, Hartikainen J, Huber K, Kala P, Klinceva M, Kristensen SD, Ludman P, Ferre JM, Merkely B, Milicic D, Morais J, Noc M, Opolski G, Ostojic M, Radovanovic D, De Servi S, Stenestrand U, Studencan M, Tubaro M, Vasiljevic Z, Weidinger F, Witkowski A, Zeymer U, European Association for Percutaneous Cardiovascular Interventions (2010) Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. Eur Heart J 31:943–957

    Article  PubMed  Google Scholar 

  2. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van’t Hof A, Widimsky P, Zahger D (2012) ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 33:2569–2619

    Article  CAS  PubMed  Google Scholar 

  3. American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Brindis RG, Creager MA, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Kushner FG, Ohman EM, Stevenson WG, Yancy CW (2013) 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. J Am Coll Cardiol 61:e78–e140

    Article  PubMed  Google Scholar 

  4. Schiele F, Hochadel M, Tubaro M, Meneveau N, Wojakowski W, Gierlotka M, Polonski L, Bassand JP, Fox KA, Gitt AK (2010) Reperfusion strategy in Europe: temporal trends in performance measures for reperfusion therapy in ST-elevation myocardial infarction. Eur Heart J 31:2614–2624

    Article  PubMed  Google Scholar 

  5. McManus DD, Gore J, Yarzebski J, Spencer F, Lessard D, Goldberg RJ (2011) Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI. Am J Med 124:40–47

    Article  PubMed Central  PubMed  Google Scholar 

  6. Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Sabaté M, Valgimigli M, Frati G, Kedhi E, Smits PC, Kaiser C, Genereux P, Galatius S, Kirtane AJ, Stone GW. Clinical outcomes with drug-eluting and bare metal stents in patients with st-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol. doi: 10.1016/j.jacc.2013.05.022

  7. Nakazawa G, Otsuka F, Nakano M, Vorpahl M, Yazdani SK, Ladich E, Kolodgie FD, Finn AV, Virmani R (2011) The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol 57:1314–1322

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R (2007) Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 115:2435–2441

    Article  PubMed  Google Scholar 

  9. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R (2006) Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48:193–202

    Article  PubMed  Google Scholar 

  10. Serruys PW, Onuma Y, Dudek D, Smits PC, Koolen J, Chevalier B, de Bruyne B, Thuesen L, McClean D, van Geuns RJ, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert KM, Sudhir K, Garcia–Garcia HM, Ormiston JA (2011) Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol 58:1578–1588

    Article  CAS  PubMed  Google Scholar 

  11. Onuma Y, Serruys PW, Perkins LE, Okamura T, Gonzalo N, García-García HM, Regar E, Kamberi M, Powers JC, Rapoza R, van Beusekom H, van der Giessen W, Virmani R (2010) Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation 122:2288–2300

    Article  CAS  PubMed  Google Scholar 

  12. Patel N, Banning AP. Bioabsorbable scaffolds for the treatment of obstructive coronary artery disease: the next revolution in coronary intervention? Heart. doi: 10.1136/heartjnl-2012-303346

  13. Ormiston JA, Serruys PW, Onuma Y, van Geuns RJ, de Bruyne B, Dudek D, Thuesen L, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert KM, Rapoza R, Garcia–Garcia HM (2012) First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study. Circ Cardiovasc Interv 5:620–632

    Article  CAS  PubMed  Google Scholar 

  14. Okamura T, Garg S, Gutiérrez-Chico JL, Shin ES, Onuma Y, García–García HM, Rapoza RJ, Sudhir K, Regar E, Serruys PW (2010) In vivo evaluation of stent strut distribution patterns in the bioabsorbable everolimus-eluting device: an OCT ad hoc analysis of the revision 1.0 and revision 1.1 stent design in the ABSORB clinical trial. EuroIntervention 5:932–938

    Article  PubMed  Google Scholar 

  15. Post F, Giannitsis E, Riemer T, Maier LS, Schmitt C, Schumacher B, Heusch G, Mudra H, Voigtländer T, Erbel R, Darius H, Katus H, Hamm C, Senges J, Gori T, Münzel T (2012) Pre- and early in-hospital procedures in patients with acute coronary syndromes: first results of the “German chest pain unit registry”. Clin Res Cardiol 101:983–991

    Article  PubMed  Google Scholar 

  16. von Scheidt W, Thilo C (2011) As time goes by?: the fallacy of thrombolysis in STEMI networks. Clin Res Cardiol 100:867–877

    Article  Google Scholar 

  17. Müller UM, Eitel I, Eckrich K, Erbs S, Linke A, Möbius-Winkler S, Mende M, Schuler GC, Thiele H (2011) Impact of minimising door-to-balloon times in ST-elevation myocardial infarction to less than 30 min on outcome: an analysis over an 8-year period in a tertiary care centre. Clin Res Cardiol 100:297–309

    Article  PubMed  Google Scholar 

  18. Liebetrau C, Szardien S, Rixe J, Woelken M, Rolf A, Bauer T, Nef H, Möllmann H, Hamm C, Weber M (2011) Direct admission versus transfer of AMI patients for primary PCI. Clin Res Cardiol 100:217–225

    Article  PubMed  Google Scholar 

  19. Nordmann AJ, Bucher H, Hengstler P, Harr T, Young J (2004) Primary stenting versus primary balloon angioplasty for treating acute myocardial infarction. Am J Med 116:253–262

    Article  PubMed  Google Scholar 

  20. Piccolo R, Cassese S, Galasso G, Niglio T, De Rosa R, De Biase C, Piscione F (2012) Long-term clinical outcomes following sirolimus-eluting stent implantation in patients with acute myocardial infarction. A meta-analysis of randomized trials. Clin Res Cardiol 101:885–893

    Article  CAS  PubMed  Google Scholar 

  21. Dziewierz A, Siudak Z, Rakowski T, Birkemeyer R, Mielecki W, Ranosz P, Dubiel JS, Dudek D (2011) Drug-eluting versus bare-metal stents in ST-segment elevation myocardial infarction: a mortality analysis from the EUROTRANSFER registry. Clin Res Cardiol 100:139–145

    Article  CAS  PubMed  Google Scholar 

  22. Scheller B, Levenson B, Joner M, Zahn R, Klauss V, Naber C, Schächinger V, Elsaesser A, Arbeitsgruppe Interventionelle Kardiologie (AGIK), der Deutschen Gesellschaft für Kardiolo-gie (DGK). Drug-eluting coronary stents and drug-coated balloon catheters. 2011 position paper of the German Cardiac Society. Kardiologe 5:411–435

  23. de Waha A, Cassese S, Park DW, Burzotta F, Byrne RA, Tada T, King LA, Park SJ, Schömig A, Kastrati A (2012) Everolimus-eluting versus sirolimus-eluting stents: an updated meta-analysis of randomized trials. Clin Res Cardiol 101:461–467

    Article  CAS  PubMed  Google Scholar 

  24. Cuneo A, Bramlage P, Hochadel M, Senges J, Nienaber C, Kuck KH, Tebbe U (2012) Concurrent drug eluting/bare metal stent implantation during percutaneous coronary intervention in target vessel: outcomes and 1-year follow-up. Clin Res Cardiol 101:281–288

    Article  CAS  PubMed  Google Scholar 

  25. Akin I, Naber C, Sabin G, Hochadel M, Senges J, Kuck KH, Nienaber C, Richardt G, Tölg R (2013) Outcome of percutaneous coronary intervention with drug-eluting stents in unprotected left main versus non-left main native coronary artery disease: results from the prospective multicenter German DES.DE registry. Clin Res Cardiol 102:679–686

    Article  CAS  PubMed  Google Scholar 

  26. Biondi-Zoccai G, Sheiban I, Moretti C, Palmerini T, Marzocchi A, Capodanno D, Tamburino C, Margheri M, Vecchi G, Sangiorgi G, Santarelli A, Bartorelli AL, Briguori C, Vignali L, Pede Fd, Ramondo A, Medda M, de Carlo M, Falsini G, Benassi A, Palmieri C, Filippone V, Sangiorgi D, Barlocco F, de Servi S (2011) Appraising the impact of left ventricular ejection fraction on outcomes of percutaneous drug-eluting stenting for unprotected left main disease: insights from a multicenter registry of 975 patients. Clin Res Cardiol 100:403–411

    Article  PubMed  Google Scholar 

  27. Rittger H, Rieber J, Kögler K, Sinha A, Schmidt M, Breithardt OA, Biggar P, Einsle F, Diegeler A, Brachmann J (2011) Clinical outcome and quality of life after interventional treatment of left main disease with drug-eluting-stents in comparison to CABG in elderly and younger patients. Clin Res Cardiol 100:439–446

    Article  CAS  PubMed  Google Scholar 

  28. Kaya E, Cuneo A, Hochadel M, Jünger C, Stepper W, Bramlage P, Kuck KH, Nienaber CA, Senges J, Eckardt L, Tebbe U, Reinecke H (2011) Impact of chronic kidney disease on the prognosis of patients undergoing percutaneous coronary interventions using drug-eluting stents. Clin Res Cardiol 100:1103–1109

    Article  PubMed  Google Scholar 

  29. Kajiya T, Liang M, Sharma RK, Lee CH, Chan MY, Tay E, Chan KH, Tan HC, Low AF (2013) Everolimus-eluting bioresorbable vascular scaffold (BVS) implantation in patients with ST-segment elevation myocardial infarction (STEMI). EuroIntervention 9:501–504

    Article  PubMed  Google Scholar 

  30. Mandelzweig L, Battler A, Boyko V, Bueno H, Danchin N, Filippatos G, Gitt A, Hasdai D, Hasin Y, Marrugat J, Van de Werf F, Wallentin L, Behar S, Euro Heart Survey Investigators (2006) The second Euro heart survey on acute coronary syndromes: characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. Eur Heart J 27:2285–2293

    Article  PubMed  Google Scholar 

  31. Vandecasteele EH, De Buyzere M, Gevaert S, de Meester A, Convens C, Dubois P, Boland J, Sinnaeve P, De Raedt H, Vranckx P, Coussement P, Evrard P, Beauloye C, Renard M, Claeys MJ (2013) Reperfusion therapy and mortality in octogenarian STEMI patients: results from the Belgian STEMI registry. Clin Res Cardiol. doi:10.1007/s00392-013-0600-3

    PubMed  Google Scholar 

  32. Schwarz AK, Zahn R, Hochadel M, Kerber S, Hauptmann KE, Glunz HG, Mudra H, Darius H, Zeymer U (2011) Age-related differences in antithrombotic therapy, success rate and in-hospital mortality in patients undergoing percutaneous coronary intervention: results of the quality control registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte (ALKK). Clin Res Cardiol 100:773–780

    Article  CAS  PubMed  Google Scholar 

  33. Dündar C, Oduncu V, Erkol A, Tanalp AC, Sırma D, Karagöz A, Karabay CY, Kılıçgedik A, Pala S, Tigen K, Izgi A, Kırma C (2012) In-hospital prognostic value of hemoglobin levels on admission in patients with acute ST segment elevation myocardial infarction undergoing primary angioplasty. Clin Res Cardiol 101:37–44

    Article  PubMed  Google Scholar 

  34. Bramlage P, Cuneo A, Zeymer U, Hochadel M, Richardt G, Silber S, Senges J, Nienaber CA, Tebbe U, Kuck KH (2013) Prognosis of patients with atrial fibrillation undergoing percutaneous coronary intervention receiving drug eluting stents. Clin Res Cardiol 102:289–297

    Article  CAS  PubMed  Google Scholar 

  35. Ndrepepa G, Tada T, Fusaro M, Cassese S, King L, Hadamitzky M, Haase HU, Schömig A, Kastrati A, Pache J (2012) Association of coronary atherosclerotic burden with clinical presentation and prognosis in patients with stable and unstable coronary artery disease. Clin Res Cardiol 101:1003–1011

    Article  PubMed  Google Scholar 

  36. de Waha S, Desch S, Eitel I, Fuernau G, Lurz P, Leuschner A, Grothoff M, Gutberlet M, Schuler G, Thiele H (2012) Relationship and prognostic value of microvascular obstruction and infarct size in ST-elevation myocardial infarction as visualized by magnetic resonance imaging. Clin Res Cardiol 101:487–495

    Article  PubMed  Google Scholar 

  37. Jensen CJ, Eberle HC, Nassenstein K, Schlosser T, Farazandeh M, Naber CK, Sabin GV, Bruder O (2011) Impact of hyperglycemia at admission in patients with acute ST-segment elevation myocardial infarction as assessed by contrast-enhanced MRI. Clin Res Cardiol 100:649–659

    Article  CAS  PubMed  Google Scholar 

  38. Afzali D, Erren M, Pavenstädt HJ, Vollert JO, Hertel S, Waltenberger J, Reinecke H, Lebiedz P (2013) Impact of copeptin on diagnosis, risk stratification, and intermediate-term prognosis of acute coronary syndromes. Clin Res Cardiol 102:755–763

    Article  CAS  PubMed  Google Scholar 

  39. Mueller M, Celik S, Biener M, Vafaie M, Schwoebel K, Wollert KC, Januzzi JL, Katus HA, Giannitsis E (2012) Diagnostic and prognostic performance of a novel high-sensitivity cardiac troponin T assay compared to a contemporary sensitive cardiac troponin I assay in patients with acute coronary syndrome. Clin Res Cardiol 101:837–845

    Article  CAS  PubMed  Google Scholar 

  40. Celik S, Giannitsis E, Wollert KC, Schwöbel K, Lossnitzer D, Hilbel T, Lehrke S, Zdunek D, Hess A, Januzzi JL, Katus HA (2011) Cardiac troponin T concentrations above the 99th percentile value as measured by a new high-sensitivity assay predict long-term prognosis in patients with acute coronary syndromes undergoing routine early invasive strategy. Clin Res Cardiol 100:1077–1085

    Article  CAS  PubMed  Google Scholar 

  41. Droppa M, Desch S, Blase P, Eitel I, Fuernau G, Schuler G, Adams V, Thiele H (2011) Impact of N-acetylcysteine on contrast-induced nephropathy defined by cystatin C in patients with ST-elevation myocardial infarction undergoing primary angioplasty. Clin Res Cardiol 100:1037–1043

    Article  CAS  PubMed  Google Scholar 

  42. Kehmeier ES, Lepper W, Kropp M, Heiss C, Hendgen-Cotta U, Balzer J, Neizel M, Meyer C, Merx MW, Verde PE, Ohmann C, Heusch G, Kelm M, Rassaf T (2012) TNF-α, myocardial perfusion and function in patients with ST-segment elevation myocardial infarction and primary percutaneous coronary intervention. Clin Res Cardiol 101:815–827

    Article  CAS  PubMed  Google Scholar 

  43. Klug G, Mayr A, Mair J, Schocke M, Nocker M, Trieb T, Jaschke W, Pachinger O, Metzler B (2011) Role of biomarkers in assessment of early infarct size after successful p-PCI for STEMI. Clin Res Cardiol 100:501–510

    Article  PubMed  Google Scholar 

  44. Theidel U, Asseburg C, Giannitsis E, Katus H (2013) Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany. Clin Res Cardiol 102:447–458

    Article  PubMed  Google Scholar 

  45. Zeymer U, Arntz HR, Mark B, Fichtlscherer S, Werner G, Schöller R, Zahn R, Diller F, Darius H, Dill T, Huber K (2012) Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial. Clin Res Cardiol 101:305–312

    Article  CAS  PubMed  Google Scholar 

  46. Desch S, Siegemund A, Scholz U, Adam N, Eitel I, de Waha S, Fürnau G, Lurz P, Wetzel S, Schuler G, Thiele H (2012) Platelet inhibition and GP IIb/IIIa receptor occupancy by intracoronary versus intravenous bolus administration of abciximab in patients with ST-elevation myocardial infarction. Clin Res Cardiol 101:117–124

    Article  CAS  PubMed  Google Scholar 

  47. Eitel I, Friedenberger J, Fuernau G, Dumjahn A, Desch S, Schuler G, Thiele H (2011) Intracoronary versus intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: 6-month effects on infarct size and left ventricular function. The randomised Leipzig immediate percutaneous coronary intervention abciximab i.v. versus i.c. in ST-elevation myocardial infarction trial (LIPSIAbciximab-STEMI). Clin Res Cardiol 100:425–432

    Article  CAS  PubMed  Google Scholar 

  48. Seivani Y, Abdel-Wahab M, Geist V, Richardt G, Sulimov DS, El-Mawardy M, Toelg R, Akin I (2013) Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents. Clin Res Cardiol. doi:10.1007/s00392-013-0592-z

    PubMed  Google Scholar 

  49. Schulz S, Mehilli J, Ndrepepa G, Dotzer F, Dommasch M, Kufner S, Birkmeier KA, Tiroch K, Byrne RA, Schömig A, Kastrati A (2011) Influence of abciximab on evolution of left ventricular function in patients with non-ST-segment elevation acute coronary syndromes undergoing PCI after clopidogrel pretreatment: lessons from the ISAR-REACT 2 trial. Clin Res Cardiol 100:691–699

    Article  CAS  PubMed  Google Scholar 

  50. Khattab AA, Ndrepepa G, Schulz S, Neumann FJ, Mehilli J, Büttner HJ, Pache J, Seyfarth M, Dirschinger J, Kastrati A, Berger PB, Schömig A, Richardt G (2011) Statin effect on thrombin inhibitor effectiveness during percutaneous coronary intervention: a post hoc analysis from the ISAR-REACT 3 trial. Clin Res Cardiol 100:579–585

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

Helge Möllmann, Christian Hamm and Holger Nef received honoraria for lectures from Abbott Vascular. All other authors have no potential conflict of interest.

Author information

Authors and Affiliations

  1. Department of Cardiology, Medizinische Klinik I, University of Giessen, Klinikstrasse 33, 35392, Giessen, Germany

    Jens Wiebe, Astrid Most, Oliver Dörr, Kay Weipert, Johannes Rixe, Christoph Liebetrau, Christian Hamm & Holger Nef

  2. Department of Cardiology, Kerckhoff Heart and Thorax Center, Benekestrasse 2-8, 61231, Bad Nauheim, Germany

    Helge Möllmann, Christoph Liebetrau & Christian Hamm

  3. Department of Cardiology, Klinikum Oldenburg, Rahel-Straus-Strasse 10, 26133, Oldenburg, Germany

    Albrecht Elsässer

  4. Department of Cardiology, Medizinische Klinik II, University of Erlangen, Ulmenweg 18, 91054, Erlangen, Germany

    Stephan Achenbach

Authors
  1. Jens Wiebe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Helge Möllmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Astrid Most
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Oliver Dörr
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kay Weipert
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Johannes Rixe
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Christoph Liebetrau
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Albrecht Elsässer
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Stephan Achenbach
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Christian Hamm
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Holger Nef
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Holger Nef.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wiebe, J., Möllmann, H., Most, A. et al. Short-term outcome of patients with ST-segment elevation myocardial infarction (STEMI) treated with an everolimus-eluting bioresorbable vascular scaffold. Clin Res Cardiol 103, 141–148 (2014). https://doi.org/10.1007/s00392-013-0630-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00392-013-0630-x

Keywords

Search

Navigation